Compare Enveric Biosciences Inc (ENVB) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Nutrien Ltd — how do they compare? Enveric Biosciences Inc trades at $1.39 (market cap $5.32M), while Nutrien Ltd trades at $67 (market cap $32.46B). The key difference: Nutrien Ltd is far larger — about 6101.5× Enveric Biosciences Inc's market cap, and Nutrien Ltd pays a 3.22% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | NTR | |
|---|---|---|
Market Cap | $5.32M | $32.46B |
Sector | Health | Basic Materials |
52-Week High | $17.40 | $83.94 |
52-Week Low | $1.28 | $53.64 |
Enterprise Value | $408.82K | $45.62B |
Dividend Yield | — | 3.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Nutrien (NTR) trades at $68.64, up 1.54% today, with a bullish technical outlook and strong analyst support. The stock shows solid fundamentals with a P/E of 13.92 and net income margin of 8.58%, while recent earnings beat expectations in two of the last three quarters. Healthy fertilizer demand and cost controls support growth, though input cost pressures persist.
Outlook remains positive with a consensus price target of $77.67, offering 13% upside. Key risks include volatile input costs and industry headwinds, but institutional buy ratings (63.6%) and stable cash flows provide a foundation for continued shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
